BioSpace News Archive

DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown , President and CEO, Dr. Norman Sussman , Chief Medical Officer, and Dr. WeiQi Lin , Executive Vice President of R&D, will be participating in a fireside chat hosted by Ed Arce , Managing Director of Equity Research at H.C. Wainwright.

Cerner Corporation (NASDAQ: CERN), Elligo Health Research® and Freenome are collaborating to enable a clinical trial through the Learning Health Network to help advance early cancer detection.

Trevena, Inc. announced that Carrie Bourdow, President & CEO and Barry Shin, CFO, will be participating in the H.C. Wainwright Global Investment Conference being held May 23 - 26, 2022.

Since the AccumTM molecule was previously shown to significantly enhance the immunogenicity of various proteins, as shown notably in our press releases dated of January 26th, 2022 and November 3rd, 2021, the Defence team engineered a novel protein-based vaccine targeting the oncogenic protein E7 normally used by HPV to transform healthy cells into an outgrowing tumor.

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced a multi-year collaboration with the National Institutes of Health to develop small molecule antiviral therapeutics to prevent pandemics.

Moderna, Inc. announced its participation in a fireside chat at the UBS 2022 Global Healthcare Conference on Tuesday, May 24th at 9:15 a.m. ET.

Outset Medical, Inc., a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced that members of management will participate in fireside chats at two upcoming investor conferences.

Finding treatment options for skin cancer may become easier with the launch of a new test by Labcorp, a leading global life sciences company.

Catalyst OrthoScience is pleased to announce that Dr. Todd Wilson has joined Catalyst as Vice President of Medical Education and Training effective immediately.

Scientists at the UC San Francisco Quantitative Biosciences Institute and the QBI Coronavirus Research Group have been initially awarded $67.5 million from the National Institute of Allergy and Infectious Diseases to support its mission of pandemic preparedness.